CA-500-GLOBAL
10.1.2022 08:17:07 CET | Business Wire | Press release
Global venture capital firm 500 Global and Ashdod Port Company (“Ashdod Port”), a leading port in Israel, have joined forces to launch the inaugural cohort of the Ashdod Port Accelerator by 500 Global.
Ashdod Port and 500 Global will select up to 14 Israeli startups for the accelerator program, which helps startups quickly test and validate partnership opportunities with Ashdod Port through an accelerated proof of concept over the course of five to six months.
For this first cohort, Ashdod Port is selecting startups with solutions in energy, seaport operations, logistics, and shipping. They will benefit from 12 weeks of masterclasses and coaching from 500 Global’s international network of mentors, and receive a full array of support and resources from the Port, including testing space for their products.
“Unlike traditional accelerator programs that focus on scaling and growth education, a startup that is selected for the Ashdod Port Accelerator by 500 Global will have tangible opportunities to dive straight into Proof of Concept and is on a fast-track to pilots, partnerships and integration opportunities with Ashdod Port. We are excited to be able to help startups in the maritime space expand and grow with an innovative partner,” said Ee Ling Lim, Executive Director of Global Programs, 500 Global.
“This past year demonstrated that the world of shipping and marine routes are important to the proper function of the global economy, when an estimated 90% of goods are transported by sea. We are breaking into a “blue ocean" that appears eager to absorb technology, and hope that we can bring the good news to other ports in the world. I congratulate 500 Global on their win and am delighted at this opportunity to work with them, and to help drive innovation in the marine world," said Shiko Zana, CEO of the Ashdod Port Board of Directors.
Applications for the Ashdod Port Accelerator by 500 Global are open from January 10 to February 3, 2022. The program and proof of concept are expected to take place from March to September 2022. Interested startups can get more information and apply via https://ecosystems.500.co/ashdod-port-accelerator
About 500 Global
500 Global is a venture capital firm with $1.8B in assets under management that invests early in founders building fast-growing technology companies. We focus on markets where technology, innovation, and capital can unlock long-term value and drive economic growth. We work closely with key stakeholders and advise governments and corporations on how best to support entrepreneurial ecosystems so startups can thrive. 500 Global has backed over 6,000 founders representing more than 2,500 companies operating in 77 countries. Our portfolio includes 41 companies valued at over $1 billion and 125 companies valued at over $100 million. Our 140+ plus team members are located in more than 15 countries and bring experience as entrepreneurs, investors, and operators from some of the world’s leading technology companies.
About Ashdod Port
Ashdod Port , the Port of Israel, is the leading sea port of the State of Israel with a strategically advantageous location, about 40 km from Tel Aviv and close to the country’s major commercial centers and highways.
This press release is intended solely for general informational or educational purposes only. 500 Global and Ashdod Port are independent third parties. This program will be operated by Ashdod Port with 500 Startups Incubator, L.L.C. and under no circumstances should any content provided as part of any such programs, services or events be construed as investment, legal, tax or accounting advice by either party. While parties have taken reasonable steps to ensure that the information contained in this press release is accurate and up-to-date, no liability can be accepted for any error or omissions. No representations are made as to specific outcomes from relying on the contents of this press release and any third party links. Under no circumstances should any content in this press release be construed as investment advice. No content or information in this press release should be construed as an offer to sell or solicitation of interest to purchase any securities of or advised by any parties herein. This is a non-investment program, and participation in the program does not include or guarantee an investment from 500 Global, Ashdod Port or their respective affiliates. However, participation in the program does not preclude 500 Global, Ashdod Port, or their affiliates from considering future investments in a participating company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220109005074/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom